Sign In
Buy ANAB
$53.36
-1.68 (-3.05%)
At Close: Jul 31, 2026
AnaptysBio Announces Participation in Upcoming Investor Conferences
04:15pm, Tuesday, 30'th May 2023
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Danie
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue Estimates
07:02pm, Thursday, 11'th May 2023
AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to loss of $1.31 per share a year ago.
AnaptysBio: Upside Could Be Lying Ahead Very Nicely
11:44pm, Thursday, 30'th Mar 2023
US-listed biotech stocks are trading even lower than before on fears of a banking system collapse, creating an opportunity to add to positions and take advantage of attractive levels. AnaptysBio, Inc.
GSK's Jemperli Effective Against First-Line Endometrial Cancer
04:45pm, Tuesday, 28'th Mar 2023
A late-stage study data shows that GSK's Jemperli reduced disease progression risk or death by 72% for treating adult patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Lags Revenue Estimates
06:48pm, Wednesday, 01'st Mar 2023
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -1.09% and 16.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference
06:56pm, Monday, 21'st Nov 2022 GlobeNewswire Inc.
SAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Da
Expert Ratings for AnaptysBio
08:07pm, Wednesday, 09'th Nov 2022 Benzinga
Over the past 3 months, 4 analysts have published their opinion on AnaptysBio (NASDAQ:ANAB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a comp
AnaptysBio to Participate in Upcoming November Investor Conferences
07:10pm, Wednesday, 09'th Nov 2022 GlobeNewswire Inc.
SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Da
AnaptysBio to Participate in Upcoming November Investor Conferences
02:10pm, Wednesday, 09'th Nov 2022
SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan
AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Misses Revenue Estimates
10:55pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -151.06% and 92.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Xenon Pharmaceuticals (XENE) Reports Q3 Loss, Misses Revenue Estimates
10:35pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -9.62% and 97.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the sto
AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Misses Revenue Estimates
07:33pm, Tuesday, 08'th Nov 2022
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -151.06% and 92.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
02:27pm, Tuesday, 01'st Nov 2022 Benzinga
Upgrades
For AnaptysBio Inc (NASDAQ:ANAB), Guggenheim upgraded the previous rating of Neutral to Buy. AnaptysBio earned $1.15 in the second quarter, compared to $0.02 in the year-ago quarter. The sto
AnaptysBio, Inc. (ANAB) Just Flashed Golden Cross Signal: Do You Buy?
01:55pm, Thursday, 13'th Oct 2022 Zacks Investment Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
GSK's (GSK) PD-1 Inhibitor Drug Meets Lung Cancer Study Goal
03:02pm, Thursday, 06'th Oct 2022 Zacks Investment Research
GSK's (GSK) mid-stage study, evaluating the combination of its cancer drug Jemperli with chemotherapy in non-small cell lung cancer, meets the primary endpoint of objective response rate.
